Aim: The present study aimed to determine the factors that affect the working life quality (WLQ) of healthcare employees and to examine the association between burnout levels and WLQ.
Subject And Methods: This cross-sectional study was conducted with 332 healthcare employees working in Kirklareli, Northwestern Turkey. The data were collected with the e-survey, which included the Personal Information Form, Working Life Quality Questionnaire (WLQQ), and Maslach Burnout Inventory-General Form (MBI-GF).
Results: A total of 54.2% of the participants, who had a mean age of 34.45±8.82, were midwives/nurses and 14.5% were physicians. It was determined that 71.1% of the participants had increased workloads, 81.6% were working outside their job descriptions during the pandemic period, and 57.8% wanted to quit their job. In the multivariate linear regression analysis, according to the adjusted models, a positive and significant association was determined between the WLQQ general dimension scores and having professional seniority of ≥10 years, and a negative association was detected with working in a secondary healthcare institution, increased workload, working outside the job description, and the desire to quit the job ( < 0.05). A positive association was detected between the WLQQ general dimension scores and the competence sub-dimension of the MBI-GF, and a significant and negative association was detected between burnout and desensitization ( < 0.05).
Conclusion: WLQ scores increased as the burnout and desensitization decreased and the competence increased among the healthcare employees. In order to raise the WLQ, initiatives must be planned to improve the working conditions of healthcare employees and reduce psychosocial risks.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926415 | PMC |
http://dx.doi.org/10.1007/s10389-023-01842-3 | DOI Listing |
Antimicrob Steward Healthc Epidemiol
December 2024
Departments of Medicine and Surgery, Washington University School of Medicine, St. Louis, MO, USA.
Objective: To estimate incidence and healthcare costs and mortality associated with infection (CDI) among adults <65 years old.
Design: Retrospective cohort study.
Patients: First CDI episodes among commercially insured US patients 18-64 years old were identified from a large claims database.
Open Forum Infect Dis
January 2025
Vaccines, Pfizer Inc, Collegeville, Pennsylvania, USA.
Background: Serotype-specific urinary antigen detection (UAD) assay results can be used to estimate the serotype contribution among adults with pneumococcal community-acquired pneumonia (CAP) and to guide recommendations regarding higher-valency pneumococcal conjugate vaccines (PCVs).
Methods: Adults aged ≥18 years hospitalized with radiographic evidence of CAP were prospectively enrolled in 4 US cities from November 2019 to December 2020, overlapping the coronavirus disease 2019 (COVID-19) pandemic. Data were collected by patient interview and medical chart review.
Front Hum Neurosci
December 2024
Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, Outpatients Department Level 2 Western General Hospital, University of Edinburgh, Edinburgh, United Kingdom.
Objectives: We assessed the modulation of allostatic load (AL) by engagement in healthy habits and life stressors, mediated through resilience and the perceived influence of the stressors. Sleep was included as third mediator given extensive evidence associating to all the analysed factors.
Methods: Structural equation models to assess the modulation of AL by either traumatic or psychosocial stressors and healthy habits were generated with data from 620 mid-life adults (age 51.
Lancet Respir Med
December 2024
Population Policy and Practice Department, UCL Great Ormond Street Institute of Child Health, University College London, London, UK; Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK. Electronic address:
Background: In phase 2 trials in people with cystic fibrosis aged 18 years and older, vanzacaftor-tezacaftor-deutivacaftor has been shown to be a safe and effective, once-daily cystic fibrosis transmembrane conductance regulator (CFTR) modulator. Restoring normal CFTR function early in life has the potential to prevent manifestations of cystic fibrosis. We aimed to evaluate the safety, tolerability, efficacy, and pharmacokinetics of vanzacaftor-tezacaftor-deutivacaftor in children with cystic fibrosis aged 6-11 years.
View Article and Find Full Text PDFLancet Respir Med
December 2024
Division of Infection, Immunity and Respiratory Medicine, University of Manchester, Manchester, UK. Electronic address:
Background: The goal of cystic fibrosis transmembrane conductance regulator (CFTR) modulators is to reach normal CFTR function in people with cystic fibrosis. Vanzacaftor-tezacaftor-deutivacaftor restored CFTR function in vitro and in phase 2 trials in participants aged 18 years and older resulting in improvements in CFTR function, as measured by sweat chloride concentrations and lung function as measured by spirometry. We aimed to evaluate the efficacy and safety of vanzacaftor-tezacaftor-deutivacaftor compared with standard of care elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!